Asklepios account plan
Private healthcare provider in Germany
At a glance
Asklepios is a family-owned German hospital group with around 160 facilities, a 73,000-strong workforce and EUR 6,401.2 million revenue in FY2025.
Asklepios (Asklepios Kliniken GmbH & Co. KGaA, Hamburg) is a family-owned German hospital group founded in 1985, running around 160 healthcare facilities in 15 federal states: university and maximum-care hospitals, basic and standard care hospitals, rehabilitation clinics, medical care centres (MVZ), nursing services and online therapy. It holds majority stakes in RHÖN-KLINIKUM AG and MEDICLIN AG and took over the City of Hamburg hospitals in 2004. FY2025 revenue was EUR 6,401.2 million (+7.4%), EBITDA EUR 586.1 million and consolidated net income EUR 151.8 million, with 3,899,121 patients treated and 31,141 beds. The group has a 73,000-strong workforce (53,194 average FTEs in 2025). The Management Board is led by co-CEOs Joachim Gemmel and Marco Walker.
Business units
Clinical acute care
86.8% of FY2025 group revenue (EUR 5,554.5 million)University hospitals such as Universitätsklinikum Marburg, maximum, basic and standard care hospitals and specialised Centers of Excellence, paid mainly by statutory health insurance through DRGs. Hamburg is the core cluster, and new regional clusters were formed in 2025 in Brandenburg/Vorpommern and Mecklenburg. Outpatient cases grew 8.1% in 2025 against 2.9% for inpatient cases.
Post-acute and rehabilitation clinics
12.2% of FY2025 group revenue (EUR 782.7 million)Rehabilitation hospitals, all certified to IQMP-kompakt, led by orthopaedic indications with growth in psychosomatic and oncological care. A new German Pension Insurance remuneration system for medical rehabilitation applies from 1 January 2026.
Social and welfare facilities and Other
1.0% of FY2025 group revenueA very limited nursing care activity (EUR 24.3 million) plus other revenue (EUR 39.7 million), down from EUR 73.1 million in 2024.
Asklepios Kliniken Hamburg GmbH
74.90%-held sub-group built on the City of Hamburg hospitals taken over in 2004; Klinik St. Georg, Klinik Nord and Klinik Harburg are among the largest 2025 investment sites. Its managing director is CMO PD Dr. Sara Sheikhzadeh.
RHÖN-KLINIKUM AG
94.65%-held sub-group based in Bad Neustadt a. d. Saale, consolidated since 3 July 2020. Closer integration drives standardised product ranges and strategic framework contracts in procurement; new service and cleaning companies were founded in 2025.
MEDICLIN AG
52.73%-held sub-group based in Offenburg, majority-owned since September 2011. MEDICLIN Flex GmbH was acquired in 2025, and some MEDICLIN subsidiaries are held for sale with the sale slated for 2026.
E-Health division
Pulso Europe (Belgium), the Minddistrict mental health platform, Insite-Intervention employee assistance programmes and Fürstenberg Institut (mental and corporate health), in which a further 10% was acquired in 2025.
Strategic priorities
- Answering the hospital reform
- Asklepios responds to the KHVVG (in force 1 January 2025) and KHAG (from 2026) with specialisation, concentrated service ranges and regional clusters pooling expertise across sites and sectors.
- Outpatientisation
- Outpatient cases rose 8.1% to 3,098,698 in 2025 and 8.9% in H1 2026; the group follows patients from MVZ and outpatient care through inpatient stay and rehab.
- Digitalisation and data
- A Health Data Hub has managed clinical and administrative data centrally since November 2025, as the base for quality management, research, AI applications and data-driven care models; Virtual Wards and telemedical triage with nursing homes are running.
- Nursing recruitment and retention
- The Group-wide NEXT LEVEL NURSING initiative covers targeted recruiting, practice-based training, optimised procedures and integration of international staff, with recruiting at home and abroad.
- Outcome-based quality
- The CMO is introducing PROMs and PREMs and quality contracts that pay for whole treatment pathways, such as physiotherapy and app-based exercises around hip and knee replacements.
- Economies of scale
- Scale in procurement, IT, billing, controlling and administration, including a centralised procurement and logistics system and own warehouse sites.
Latest results
In H1 2026 (1 January to 30 June) revenue rose 4.8% to EUR 3,297.8 million and EBITDA 8.1% to EUR 323.4 million, lifting the margin to 9.8% from 9.5%; EAT was EUR 90.2 million. Patients rose 8.0% to 2,086,056, with outpatient cases up 8.9% and inpatient cases up 4.5%. Personnel costs rose 8.2% to EUR 2,318.2 million, 70.3% of revenue, on 54,650 FTEs; EUR 62.9 million of grant income for transformation costs helped results. Operating cash flow rose 30.7% to EUR 301.3 million and net debt/EBITDA was 2.4x. The 2026 forecast of roughly 2.0% organic growth and a slight improvement in key indicators was confirmed.
Investments and deals
- Capex programme
- Capex was EUR 602.5 million in 2025 (+25.8%, 9.4% of revenue), of which EUR 253.8 million subsidised, and EUR 180.1 million in H1 2026.
- Central IT and data
- Central IT investments were EUR 40.4 million in 2025, the largest single item, and Group-wide IT EUR 4.6 million in H1 2026.
- Procurement and logistics
- A centralised procurement and logistics system (EUR 11.6 million in 2025), own warehouse sites at Bad Oldesloe and Frankfurt, and a central warehouse in Bavaria (EUR 7.4 million in H1 2026).
- Hospital sites
- Main 2025 site investments were Klinik St. Georg (EUR 12.3 million), Universitätsklinikum Marburg (EUR 11.9 million), Klinik Nord (EUR 9.6 million) and Klinikum Frankfurt (Oder) (EUR 9.4 million).
- Social promissory note
- A first social Schuldschein of EUR 600.0 million was placed in October 2025 to refinance 2025, 2026 and 2027 maturities early.
Challenges and risks
- Personnel costs and staff shortage
- Employee benefits expense reached 70.3% of revenue in H1 2026 (68.1% a year earlier); personnel risk, including staff shortage, PpUGV staffing rules and wage agreements, is rated medium for 2026.
- Hospital reform uncertainty
- Management warns the reform's long-term impact is not yet certain and may bring additional adverse effects on earnings; it criticises structural rather than outcome-based quality measurement.
- Billing and budget risk
- Service, revenue, documentation and budget risks, including billing disputes, structural requirements and hybrid DRGs, are rated medium for 2026.
- Construction and investment risk
- Cost overruns, falling grant ratios and climate-related needs are rated medium; the overall risk position increased versus the previous year.
What leadership says
“financial success and sustainable growth are essential foundations for delivering the highest standard of medical care”
“Modern data platforms, AI-based applications and digital networking create new opportunities to reduce the workload of our staff”
“many hospitals in Germany have responded with ad hoc, short-term solutions, leaving them in a state of near-perpetual crisis”
“Wir haben noch nie so viel eingestellt”
Where a supplier can help
- Staff workload reduction
- Tied to the personnel cost challenge and the digitalisation priority: tools that cut documentation and administrative work for clinicians fit a group whose personnel costs reached 70.3% of revenue and whose board looks to AI to reduce staff workload.
- Nursing recruiting and onboarding
- Tied to the NEXT LEVEL NURSING initiative: recruiting, international staff integration and training offerings support a group that says it has never hired so much.
- Data, AI and telemedicine
- Tied to the Health Data Hub and Virtual Wards: suppliers of clinical data integration, remote monitoring and device-to-hospital-information-system connectivity have a live programme to plug into.
- Revenue cycle and billing
- Tied to the billing and budget risk: coding, documentation and billing-dispute tools address a risk rated medium for 2026 amid hybrid DRGs.
- Centralised procurement and logistics
- Tied to the procurement and logistics investments: framework-contract suppliers and logistics technology match the push for standardised product ranges across RHÖN-KLINIKUM and the wider group.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Asklepios?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- ASKLEPIOS Annual Report 2025
- ASKLEPIOS (Asklepios Kliniken GmbH & Co. KGaA, Hamburg) calls itself Germany's leading private family-owned hospital operator: around 160 healthcare facilities in 15 federal states, 73,000-strong workforce, 31,141 beds; sub-groups RHÖN-KLINIKUM AG (94.65%) and MEDICLIN AG (52.73%), plus Asklepios Kliniken Hamburg GmbH (74.90%).
- FY2025: revenue EUR 6,401.2 million (+7.4%), EBITDA EUR 586.1 million (+2.9%, margin 9.2%), EBIT EUR 260.3 million, consolidated net income (EAT) EUR 151.8 million (+8.5%); 3,899,121 patients (+7.0%), 628,549 cost weights (+3.3%).
- Revenue mix: 86.8% acute care hospitals, 12.2% rehabilitation clinics, 1.0% social welfare and other facilities; outpatient cases grew 8.1% to 3,098,698 versus 2.9% for inpatient cases (800,423), confirming the shift to outpatient care.
- Employee benefits expense rose 9.8% to EUR 4,339.0 million (67.8% of revenue) on 53,194 average FTEs (+4.5%) and wage rises; cost of materials ratio fell to 23.1% from 24.4% on lower energy prices, process optimisation and strategic purchasing.
- Capex of EUR 602.5 million (+25.8%, 9.4% of revenue), of which EUR 253.8 million subsidised; internal financing ratio 57.9%; largest items central IT (EUR 40.4 million), Klinik St. Georg Hamburg and Universitätsklinikum Marburg.
- Strong balance sheet: equity ratio 32.5%, net debt ratio 2.5x (target range 2.5x-3.0x), interest coverage 10.3x; first social promissory note (Schuldschein) of EUR 600.0 million placed in October 2025 to refinance 2025-2027 maturities.
- Strategy: answer the hospital reform (KHVVG/KHAG) with specialisation, outpatientisation, regional clusters (first in Brandenburg/Vorpommern and Mecklenburg), the Group-wide "NEXT LEVEL NURSING" initiative and a Health Data Hub live since November 2025.
- 2026 guidance: organic growth of roughly 2.0% with a slight increase in EBITDA, EBIT and EAT, stable equity ratio and slightly positive cost weights.
- Main risks rated "medium" for 2026: personnel; service, revenue, documentation and budget; financial; construction and investment. Overall risk has increased versus the previous year, with no existential risk identified.
- ASKLEPIOS Consolidated Interim Report H1 2026 (1 January to 30 June 2026)
- H1 2026 revenue EUR 3,297.8 million (+4.8%), EBITDA EUR 323.4 million (+8.1%, margin 9.8% vs 9.5%), EBIT EUR 159.7 million, EAT EUR 90.2 million (margin 2.7%).
- Volumes: 2,086,056 patients (+8.0%); inpatient cases 412,964 (+4.5%), outpatient cases 1,673,092 (+8.9%); cost weights 327,112 (+3.7%); beds 31,653.
- Revenue split: 78.9% acute care hospitals, 21.1% post-acute and rehabilitation clinics and other social welfare facilities; clinical acute care EUR 2,600.9 million, post-acute and rehab EUR 662.7 million.
- Personnel cost pressure: employee benefits expense +8.2% to EUR 2,318.2 million, 70.3% of revenue (68.1%), on 54,650 FTEs (+4.1%), wage increases and higher social security contributions.
- Operating cash flow EUR 301.3 million (+30.7%); capex EUR 180.1 million (5.5% of revenue), led by a central warehouse in Bavaria (EUR 7.4 million) and Group-wide IT (EUR 4.6 million).
- Balance sheet: equity ratio 32.7%, net debt/EBITDA LTM 2.4x, liquidity reserves EUR 2,125.7 million; EUR 62.9 million of grant income for transformation costs recognised.
- Forecast for 2026 confirmed: moderate organic revenue growth and a slight improvement in key performance indicators; the hospital reform may still bring adverse earnings effects.
- Management stresses the network with RHÖN-KLINIKUM AG and MEDICLIN AG, the regional clusters set up last year, and data platforms and AI to reduce staff workload.
- Level Up Klinikführung Episode 09: Schwarzwaldklinik war gestern - wie Ergebnisqualität Klinikführung neu schreibt (transcript)
- PD Dr. Sara Sheikhzadeh, CMO of the Asklepios group and managing director of Asklepios Kliniken Hamburg, on the CB "Level Up Klinikführung" podcast (episode 09, November 2025), on how hospitals and medical leadership will look by 2045.
- She treats the reform and cost pressure as an opportunity, framing a double tsunami: rising demand from demographics and medical progress against a shortage of skilled staff.
- Staff retention is the decisive competitive factor: whoever holds qualified staff can deliver services; she says Asklepios has never hired as much.
- Asklepios pushes "menschenzentrierte Medizin" (human-centred medicine), measuring outcomes with PROMs and PREMs and signing quality contracts that pay for whole treatment pathways (e.g. pre-op physiotherapy and app-based exercises for hip and knee replacements).
- Vision for 2045: hub-and-spokes, with "Leuchttürme" (lighthouse centres) concentrating complex procedures, near-home basic care, outpatient care, rehab and a strong emergency network.
- Asklepios runs around 170 facilities including a large MVZ network (GP practices, radiology, labs) and a "Asklepios hilft" patient-guidance approach across sectors.
- Telemedicine 2.0: Virtual Wards modelled on the NHS, run as an Innovation Fund project, plus telemedical triage with nursing homes; a new Group division "Bildung und Wissensmanagement" and the online learning platform ASKNow.
- She opposes structural-quality metrics in favour of outcome quality, and expects flatter, team-based medical leadership replacing the classic chief physician model.
- Sheikhzadeh: "Reichweite ist für mich ein Mittel, kein Selbstzweck" (BibliomedManager interview)
- Short written interview (BibliomedManager, 1 December 2025) with PD Dr. Sara Sheikhzadeh, Chief Medical Officer on the Asklepios Kliniken management board since mid-2022, on how she uses LinkedIn.
- Active on LinkedIn since 2022, when she joined the Asklepios board; she has gained more than 14,000 followers.
- Goal: give insight into Asklepios's strategic and medical work and drive public dialogue on digitalisation, patient safety and developing young talent.
- She treats LinkedIn as an employer-branding and recruiting instrument for Asklepios.
- Topics she posts on: digitalisation in radiology, Virtual Ward, PROMs and value-based healthcare, plus leadership and team culture, Speak Up culture, diversity and innovation.
- Expects LinkedIn to grow in importance for hospital managers in times of reform, skills shortage and social change.
- Background: internist and cardiologist, formerly head of the central emergency department at Asklepios Klinik Harburg and Asklepios Klinik St. Georg in Hamburg, and spokesperson for all seven Asklepios emergency departments in Hamburg.
Questions about Asklepios
What does Asklepios do?
Asklepios is a family-owned German healthcare group running around 160 facilities in 15 federal states, including acute hospitals, university hospitals, rehabilitation clinics, medical care centres and nursing services.
What is Asklepios's revenue?
FY2025 revenue was EUR 6,401.2 million (+7.4%), with EBITDA of EUR 586.1 million and net income of EUR 151.8 million. H1 2026 revenue was EUR 3,297.8 million.
How many employees does Asklepios have?
A 73,000-strong workforce, with 53,194 average FTEs in 2025 and 54,650 FTEs in H1 2026.
Who leads Asklepios?
The Management Board comprises co-CEOs Joachim Gemmel and Marco Walker, CFO Hafid Rifi and CMO PD Dr. Sara Sheikhzadeh. The group is family-owned and was founded on the vision of Dr. Bernard große Broermann.
What is Asklepios's strategy?
Specialisation and regional clusters in response to the German hospital reform, a shift to outpatient care, digitalisation through its Health Data Hub, and nursing recruitment through NEXT LEVEL NURSING.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)